title: Competition for talin results in trans-dominant inhibition of integrin activation.
abstract: The ability of integrin adhesion receptors to undergo rapid changes in affinity for their extracellular ligands (integrin activation) is essential for the development and function of multicellular animals and is dependent on interactions between the integrin beta subunit-cytoplasmic tail and the cytoskeletal protein talin. Cross-talk among different integrins and between integrins and other receptors impacts many cellular processes including adhesion, spreading, migration, clot retraction, proliferation, and differentiation. One form of integrin cross-talk, transdominant inhibition of integrin activation, occurs when ligand binding to one integrin inhibits the activation of a second integrin. This may be relevant clinically in a number of settings such as during platelet adhesion, leukocyte trans-migration, and angiogenesis. Here we report that competition for talin underlies the trans-dominant inhibition of integrin activation. This conclusion is based on our observations that (i). beta tails selectively defective in talin binding are unable to mediate trans-dominant inhibition, (ii). trans-dominant inhibition can be reversed by overexpression of integrin binding and activating fragments of talin, and (iii). expression of another non-integrin talin-binding protein, phosphatidylinositol phosphate kinase type Igamma-90, also inhibits integrin activation. Thus, the sequestration of talin by the suppressive species is both necessary and sufficient for trans-dominant inhibition of integrin activation.
authors.affiliation: Deptartment of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, USA. calderwood@yale.edu
authors.forename: David A
authors.initials: DA
authors.lastname: Calderwood
authors.forename: Vera
authors.initials: V
authors.lastname: Tai
authors.forename: Gilbert
authors.initials: G
authors.lastname: Di Paolo
authors.forename: Pietro
authors.initials: P
authors.lastname: De Camilli
authors.forename: Mark H
authors.initials: MH
authors.lastname: Ginsberg
mesh_terms: D000818:Animals; D001665:Binding Sites; D016466:CHO Cells; D006224:Cricetinae; D016023:Integrins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D008024:Ligands; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics / Q000378:metabolism; D017354:Point Mutation; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D021122:Protein Subunits / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D016608:Talin / Q000235:genetics / Q000378:metabolism*
chemical_list: D016023:Integrins; D008024:Ligands; D021122:Protein Subunits; D011993:Recombinant Fusion Proteins; D016608:Talin; D017853:Phosphotransferases (Alcohol Group Acceptor)